Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 

Click here to view
our current issue



 
 

Innovations in Cell-Line Development

IPT: With increasingly sophisticated biologics coming to market, and an emphasis on speed, how is biopharma meeting the cell manufacturing demands of these products? Seahee Kim: Increasingly, cell-line development (CLD) is being outsourced to external CDMO partners to help accelerate products to patients. Methods and technical offerings in the biopharmaceutical contract development and manufacturing space have led to dramatic time reductions in CLD and further efficiencies in upstream and downstream processes. These advancements have helped to speed drug products to market.

In addition, continuous process improvement and years of experience with applied molecular and genetic science in this area have had a significant impact. Biomanufacturers are now able to develop more therapeutically valuable drugs faster than ever before, and manufacture them more efficiently as well.

Seahee Kim at Samsung Biologics (October 2021)

    View full article    |    Back to Manufacturing section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | caitlin@samedanltd.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |